Qiagen N.V. (QGEN)

Market Cap	9.47B
Revenue (ttm)	1.96B
Net Income (ttm)	484.93M
Shares Out	228.04M
EPS (ttm)	2.12
PE Ratio	28.63
Forward PE	19.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	764,505
Open	41.43
Previous Close	41.45
Day's Range	41.26 - 41.67
52-Week Range	34.74 - 51.18
Beta	0.43
Analysts	Buy
Price Target	50.50 (+21.66%)
Earnings Date	Oct 30, 2023

About QGEN

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample mate...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 1996
• Employees: 6,178
• Stock Exchange: NYSE
• Ticker Symbol: QGEN

Financial Performance

In 2022, Qiagen's revenue was $2.14 billion, a decrease of -4.82% compared to the previous year's $2.25 billion. Earnings were $575.66 million, an increase of 7.19%.

Analyst Forecast

According to 4 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is $50.5, which is an increase of 21.66% from the latest price.

Price Target

$50.5

(21.66% upside)

Analyst Consensus: Buy